MX2009010477A - Nueva combinacion para su uso en el tratamiento de trastornos inflamatorios. - Google Patents

Nueva combinacion para su uso en el tratamiento de trastornos inflamatorios.

Info

Publication number
MX2009010477A
MX2009010477A MX2009010477A MX2009010477A MX2009010477A MX 2009010477 A MX2009010477 A MX 2009010477A MX 2009010477 A MX2009010477 A MX 2009010477A MX 2009010477 A MX2009010477 A MX 2009010477A MX 2009010477 A MX2009010477 A MX 2009010477A
Authority
MX
Mexico
Prior art keywords
treatment
inflammatory disorders
new combination
solvate
pharmaceutically
Prior art date
Application number
MX2009010477A
Other languages
English (en)
Inventor
Johan Raud
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of MX2009010477A publication Critical patent/MX2009010477A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proveen productos de combinación que comprenden (a) suplatast, o una sal o solvato farmacéuticamente aceptable del mismo; y (b) una estatina, o una sal o solvato farmacéuticamente aceptable de la misma; dichos productos de combinación encuentran utilidad particular en el tratamiento de aterosclerosis y condiciones relacionadas.
MX2009010477A 2007-03-30 2008-03-31 Nueva combinacion para su uso en el tratamiento de trastornos inflamatorios. MX2009010477A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92059607P 2007-03-30 2007-03-30
PCT/GB2008/001142 WO2008119988A1 (en) 2007-03-30 2008-03-31 New combination for use in the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
MX2009010477A true MX2009010477A (es) 2009-10-19

Family

ID=38328309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010477A MX2009010477A (es) 2007-03-30 2008-03-31 Nueva combinacion para su uso en el tratamiento de trastornos inflamatorios.

Country Status (16)

Country Link
US (1) US20100056552A1 (es)
EP (1) EP2129368B1 (es)
JP (1) JP2010523486A (es)
KR (1) KR20090125077A (es)
CN (1) CN101668521A (es)
AT (1) ATE494892T1 (es)
AU (1) AU2008234667A1 (es)
BR (1) BRPI0809302A2 (es)
CA (1) CA2682572A1 (es)
DE (1) DE602008004469D1 (es)
EA (1) EA200901327A1 (es)
ES (1) ES2385940T3 (es)
IL (1) IL201168A0 (es)
MX (1) MX2009010477A (es)
WO (1) WO2008119988A1 (es)
ZA (1) ZA200906188B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011065444A1 (ja) * 2009-11-27 2011-06-03 学校法人東海大学 抗血栓剤
KR20200045496A (ko) * 2017-08-29 2020-05-04 콘리그 파마 에이피에스 수플라타스트 토실레이트를 포함하는 조성물
CN112654357B (zh) * 2018-07-06 2024-02-13 阿尔杰农制药股份有限公司 用于治疗非酒精性脂肪性肝炎的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0914102T3 (da) * 1996-05-24 2006-01-09 Angiotech Pharm Inc Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
JP2001335473A (ja) * 2000-05-31 2001-12-04 Taisho Pharmaceut Co Ltd 鼻閉改善剤
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
EP1550461A1 (en) * 2002-06-26 2005-07-06 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
TW200408393A (en) * 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
SG175477A1 (en) * 2005-01-31 2011-11-28 Mylan Lab Inc Hydroxylated nebivolol metabolites

Also Published As

Publication number Publication date
WO2008119988A1 (en) 2008-10-09
ZA200906188B (en) 2010-06-30
CA2682572A1 (en) 2008-10-09
EP2129368A1 (en) 2009-12-09
CN101668521A (zh) 2010-03-10
US20100056552A1 (en) 2010-03-04
JP2010523486A (ja) 2010-07-15
EP2129368B1 (en) 2011-01-12
EA200901327A1 (ru) 2010-02-26
DE602008004469D1 (de) 2011-02-24
KR20090125077A (ko) 2009-12-03
BRPI0809302A2 (pt) 2014-10-14
ATE494892T1 (de) 2011-01-15
ES2385940T3 (es) 2012-08-03
AU2008234667A1 (en) 2008-10-09
IL201168A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
AU319601S (en) Bottle
IL197161A0 (en) Derivatives of 4-(n-azacycloalkyl)anilides and compositions containing the same
WO2009007673A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist
MX2009006507A (es) Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios.
MX2007011493A (es) Modalidades antiinflamatorias.
MY160226A (en) New process for the synthesis of (7-methoxy-1-naphthyl) acetonitrile and application in the synthesis of agomelatine
WO2009007675A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
AU326091S (en) A cabinet
IL201168A0 (en) New combination for use in the treatment of inflammatory disorders
WO2008118409A3 (en) Bone screw apparatus and related methods of use
WO2009007679A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
WO2009007674A3 (en) Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
GB201002970D0 (en) Low overhead/power saving processor synchronization mechanism and applications thereof
ATE543501T1 (de) Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen
CA117082S (en) Handle
WO2009007680A3 (en) Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
AU319040S (en) Bottle
GB0502669D0 (en) Swivel laptop/utility table
AU321369S (en) Saw blade
AU314743S (en) Motivation lines finbox
AU312677S (en) Shower enclosure
AU315174S (en) Scraper
UA29769U (ru) Применение мигрепина как вещества с противовоспалительными и жаропонижающими свойствами
AU311906S (en) Flashing
AU309534S (en) Work lamp